Diabetes Medicine Pulled Over Carcinogen ConcernsNewser — Bob Cronin
The Food and Drug Administration has posted the voluntary recall of another metformin—the ninth brand pulled since May. Riomet ER, a Type 2 diabetes medicine marketed by Sun Pharmaceutical, was found in tests to contain too much N-nitrosodimethylamine, a carcinogen, the Miami Herald reports.
The recall applies to Lot AB06381: 500mg tablets of metformin hydrochloride labeled for extended-release oral suspension, with an expiration date of October 2021. The FDA posts a roundup of its NDMA announcements here.
(NDMA also was a concern when retail chains dropped Zantac last year.)
- Where It Began: Team Debates Mask Rule for 'Sweet Caroline'
- It'll Feel Like Eating Pop Rocks, but Your Tinnitus May Improve
- Chief of Staff's New Headache: Daughter's 'Lavish' Wedding
This article originally appeared on Newser: Diabetes Medicine Pulled Over Carcinogen Concerns